In a bid to expand its reach and impact in the healthcare industry, AstraZeneca has announced the launch of Evinova, a new health-tech business. Focusing on clinical trial design and study delivery, Evinova aims to provide solutions to trial sponsors, clinical research organizations, care teams, and patients at a larger scale. By doing so, the pharmaceutical giant hopes to reduce the time and cost of developing new medicines, bring care closer to patients’ homes, and decrease the burden on health systems.

To bring Evinova’s innovative digital health solutions to a wider audience, AstraZeneca has formed major collaborations with Parexel and Fortrea. These partnerships will enable Evinova’s offerings to be made available to a broad customer base, supporting the company’s mission of improving patient care, driving healthcare transformation, and reducing carbon emissions.

AstraZeneca’s Chief Executive, Pascal Soriot, expressed his confidence in Evinova’s ability to combine scientific expertise with AI-enabled digital technologies at scale. He believes that this combination offers a real opportunity for positive change in the healthcare industry.

For more information about Evinova and its partnerships with Parexel and Fortrea, contact Michael Susin at michael.susin@wsj.com.